Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis
- 319 Downloads
This meta-analysis was conducted to compare the efficacy and safety of fulvestrant with aromatase inhibitors in postmenopausal women with hormone receptor-positive (estrogen and/or progesterone receptor positive) advanced breast cancer.
Electronic databases were searched for randomized controlled trials comparing the efficacy and safety of fulvestrant with three aromatase inhibitors (anastrozole/letrozole/exemestane) published through August 31, 2017. Time to progression/progression-free survival was the primary outcome, while overall survival and safety were the secondary outcomes. Time to progression/progression-free survival was evaluated in subgroups determined on age, hormone receptor status, visceral metastasis, and measurable disease. Hazard ratios with 95% confidence intervals were analyzed by STATA 12.0.
Total of seven randomized controlled trials, with 3168 patients were included for analysis. In the overall population, fulvestrant and aromatase inhibitors had similar time to progression/progression-free survival (Hazard ratio 0.93; 95% confidence interval 0.86–1.01, P = 0.102); however, time to progression/progression-free survival for fulvestrant 500 mg was significantly longer compared with aromatase inhibitors (hazard ratio 0.75; 95% confidence interval 0.62–0.91, P = 0.003). Subgroup analysis revealed significant prolongation of time to progression/progression-free survival with fulvestrant compared with aromatase inhibitors in the patients of estrogen and progesterone receptor-positive (hazard ratio 0.86; 95% confidence interval, 0.75–0.98, P = 0.022) and patients aged ≥ 65 years (hazard ratio 0.81; 95% confidence interval 0.68–0.96, P = 0.014). Overall survival was similar in both groups (hazard ratio 0.89; 95% confidence interval 0.70, 1.13, P = 0.334).
In postmenopausal women with estrogen and/or progesterone receptor-positive advanced breast cancer, fulvestrant 500 mg showed better efficacy than aromatase inhibitor, which was not seen with fulvestrant 250 mg. Compared to aromatase inhibitors, fulvestrant prolonged time to progression/progression-free survival in the subgroups including estrogen and progesterone receptor-positive patients and those aged ≥ 65 years.
KeywordsAdvanced breast cancer Hormone receptor Fulvestrant Aromatase inhibitors Postmenopausal
The authors acknowledge Dr. Priyanka Nair and Karan Sharma from Indegene Pvt. Ltd. for medical writing assistance during the development of this manuscript, as funded by AstraZeneca Pharmaceutical Company Ltd.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 11.Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. J Clin Oncol 28:4594–4600. https://doi.org/10.1200/JCO.2010.28.8415 CrossRefPubMedGoogle Scholar
- 14.Telford C, Jones N, Livings C, Batson S (2016) Network meta-analysis comparing overall survival for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer following failure on prior endocrine therapy. Clin Breast Cancer 16:188–195. https://doi.org/10.1016/j.clbc.2016.02.007 CrossRefPubMedGoogle Scholar
- 16.Cope S, Ouwens MJNM, Jansen JP, Schmid P (2013) Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health 16:403–417. https://doi.org/10.1016/j.jval.2012.10.019 CrossRefPubMedGoogle Scholar
- 17.Bachelot T, McCool R, Duffy S et al (2014) Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat 143:125–133. https://doi.org/10.1007/s10549-013-2778-5 CrossRefPubMedGoogle Scholar
- 24.Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, Is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403. https://doi.org/10.1200/JCO.2002.10.057 CrossRefPubMedGoogle Scholar
- 25.Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American Trial. J Clin Oncol 20:3386–3395. https://doi.org/10.1200/JCO.2002.10.058 CrossRefPubMedGoogle Scholar
- 26.Xu B, Jiang Z, Shao Z et al (2011) Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol 67:223–230. https://doi.org/10.1007/s00280-010-1483-x CrossRefPubMedGoogle Scholar
- 27.Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14:989–998. https://doi.org/10.1016/S1470-2045(13)70322-X CrossRefPubMedGoogle Scholar
- 28.Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, Advanced Breast Cancer: Results From EFECT. J Clin Oncol 26:1664–1670. https://doi.org/10.1200/JCO.2007.13.5822 CrossRefPubMedGoogle Scholar
- 30.Robertson JFR, Bondarenko IM, Trishkina E et al (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388:2997–3005. https://doi.org/10.1016/S0140-6736(16)32389-3 CrossRefPubMedGoogle Scholar
- 31.Howell A, Robertson JFR, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613. https://doi.org/10.1200/JCO.2004.02.112 CrossRefPubMedGoogle Scholar
- 37.Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35. https://doi.org/10.1016/S1470-2045(14)71159-3 CrossRefPubMedGoogle Scholar